secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021512
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon reports Q3 2022 net loss of $35.1M, cash $269.5M; pipeline updates in Jan 2023
--------------------------------------------------------------------------------

- Net loss of $35.1M ($0.51 per share) vs $35.6M ($0.93 per share) in Q3 2021.
- Cash & equivalents $269.5M as of Sep 30, 2022; runway into H2 2025.
- R&D expenses $27.9M and G&A $8.2M, both essentially flat year-over-year.
- Portfolio updates across autoimmune, neurodegeneration and ophthalmology franchises planned for Jan 2023.
- ANX005 HD Phase 2 data shows reduced neuroinflammation; regulator engagement by year-end; ANX007 GA Phase 2 data expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017022021512/0000950170-22-021512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017022021512/annx-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer